Huizenga Theodore Alan's Form 4 filing
Ultragenyx Pharmaceutical Inc. (RARE) · filed Sep 11, 2023
- Accession no.
- 0001209191-23-048905
- Filed
- Sep 11, 2023
- Trade date
- Sep 7, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $88.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Huizenga Theodore AlanCIK 0001603347 | Officer (SVP, Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 7, 2023 | Common Stock | MOption exerciseAcquired | +2,000 | $21.00 | +$42,000 | 25,777 | Direct | |
| Sep 7, 2023 | Common Stock | SSaleDisposed | −2,000 | $41.00 | −$82,000 | 23,777 | Direct | |
| Sep 7, 2023 | Common Stock | SSaleDisposed | −163 | $38.34 | −$6,249.42 | 23,614 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 7, 2023 | Common Stock | MOption exerciseDisposed | −2,000 | $0.00 | $0 | 3,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.